Related Experiment Video
Updated: May 14, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
[EGFR mutation status in Uighur lung adenocarcinoma patients]
Li Shan1, Yan Zhang, Feng Zhao
1Affiliated Cancer Hospital, Xinjiang Medical University, Urumuqi 830000, China.
Background And Objective:
Epidermal growth factor receptor (EGFR), a transmembrane protein, is a member of the tyrosine kinase family. Gefitinib, an EGFR tyrosine-kinase inhibitors, has shown a high response rate in the treatment of lung cancer in patients with EGFR mutation. However, significant differences in EGFR mutations exist among different ethnic groups. The aim of this study is to investigate the prevalence of EGFR mutations in Uighur lung adenocarcinoma patients by using a rapid and sensitive detection method and to analyze EGFR mutation differences compared with Han lung adenocarcinoma patients.
Methods:
We examined lung adenocarcinoma tissues from 138 patients, including 68 Uighur lung adenocarcinoma patients and 70 Han lung adenocarcinoma patients, for EGFR mutations in exons 18, 19, 20, and 21 by using the amplification refractory mutation system (ARMS) PCR method. The mutation differences between Uighur and Han lung adenocarcinoma were compared by using the chi-square test method.
Results:
EGFR mutations were detected in 43 (31.2%) of the 138 lung adenocarcinoma patients. EGFR mutations were detected in 11 (16.2%) of the 68 Uighur lung adenocarcinoma patients and in 32 (45.7%) of the 70 Han lung adenocarcinoma patients. Significant differences were observed in the EGFR mutations between Uighur lung adenocarcinoma patients and Han lung adenocarcinoma patients (P<0.001).
Conclusions:
Our results indicate that the EGFR mutation in Uighur lung adenocarcinoma patients (16.2%) is significantly lower than that in Han lung adenocarcinoma patients (45.7%).
Insights
Epidermal growth factor receptor (EGFR) mutations are significantly less common in Uighur lung adenocarcinoma patients (16.2%) compared to Han patients (45.7%). This finding highlights ethnic disparities in EGFR mutation prevalence for lung cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) is a key target in lung cancer therapy.
- EGFR tyrosine-kinase inhibitors (TKIs) like gefitinib show efficacy in patients with EGFR mutations.
- Ethnic variations in EGFR mutation prevalence are recognized in lung adenocarcinoma.
Purpose of the Study:
- To determine the prevalence of EGFR mutations in Uighur lung adenocarcinoma patients.
- To compare EGFR mutation rates between Uighur and Han lung adenocarcinoma cohorts.
- To utilize a rapid and sensitive detection method for EGFR mutations.
Main Methods:
- Lung adenocarcinoma tissues from 138 patients (68 Uighur, 70 Han) were analyzed.
- EGFR mutations in exons 18, 19, 20, and 21 were detected using Amplification Refractory Mutation System (ARMS) PCR.
- Chi-square test was employed to compare mutation differences between ethnic groups.
Main Results:
- EGFR mutations were found in 31.2% of all lung adenocarcinoma patients studied.
- Prevalence of EGFR mutations was 16.2% in Uighur patients and 45.7% in Han patients.
- A statistically significant difference (P<0.001) in EGFR mutation rates was observed between the two ethnic groups.
Conclusions:
- EGFR mutation rates in Uighur lung adenocarcinoma patients are significantly lower than in Han patients.
- These findings underscore ethnic disparities in EGFR mutation prevalence, impacting targeted therapy selection.
- Further research into genetic variations influencing EGFR mutations across ethnicities is warranted.